Sugi Predict

Sugi Predict / Compounds / SCHEMBL1220183

SCHEMBL1220183

SCHEMBL1220183

O=C(O)CNC(=O)c1ccc2ccccc2n1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4C Q9H3R0 1/20 1.00
▸ ALDH1A1 P00352 3/20 0.66
▸ GAA P10253 2/20 0.66
▸ MAPT P10636 2/20 0.66
▸ HDAC8 Q9BY41 1/20 0.63
▸ HPGD P15428 2/20 0.62
▸ RAB9A P51151 4/20 0.62
▸ SMN1; SMN2 Q16637 3/20 0.62
▸ NFKB1 P19838 1/20 0.62
▸ NFKB2 Q00653 1/20 0.62
▸ RELA Q04206 1/20 0.62
▸ NPC1 O15118 3/20 0.59
▸ MGAM O43451 1/20 0.59
▸ OPRM1 P35372 1/20 0.56
▸ OPRK1 P41145 1/20 0.56
▸ TMEM97 Q5BJF2 1/20 0.56
▸ SIGMAR1 Q99720 1/20 0.56
▸ MEN1 O00255 2/20 0.56
▸ KMT2A Q03164 2/20 0.56
▸ TP53 P04637 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1742676 0.82 KDM4C (0.69) KDM4CALDH1A1GAAMAPTHDAC8
SCHEMBL22819412 0.82 KDM4C (0.69) KDM4CALDH1A1GAAMAPTHDAC8
SCHEMBL5095301 0.82 ALDH1A1 (0.73) KDM4CALDH1A1GAAMAPTHDAC8
SCHEMBL13073430 0.80 MEN1 (0.74) KDM4CALDH1A1GAAMAPTHDAC8
SCHEMBL2551255 0.80 ALDH1A1 (1.00) KDM4CALDH1A1GAAMAPTHDAC8
SCHEMBL10288646 0.79 ALDH1A1 (0.74) KDM4CALDH1A1GAAMAPTHDAC8
SCHEMBL19944607 0.79 KDM4C (0.66) KDM4CALDH1A1GAAMAPTHDAC8
SCHEMBL19380241 0.79 ALDH1A1 (0.69) KDM4CALDH1A1GAAMAPTHDAC8
SCHEMBL13381527 0.79 HDAC8 (0.76) KDM4CALDH1A1GAAMAPTHDAC8
SCHEMBL31733635 0.79 KDM4C (0.65) KDM4CMAPTCYP1A2CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102552262-A Methods of increasing endogenous erythropoietin EPO FIBROGEN INC 2012-07-11 — — CN claimed
CN-102526044-A Methods of increasing endogenous erythropoietin EPO FIBROGEN INC 2012-07-04 — — CN claimed
US-8202834-B2 Fat regulation FIBROGEN, INC. (US) 2012-06-19 — — US claimed
US-20100168152-A1 Fat regulation FIBROGEN, INC. (US) 2010-07-01 — — US claimed
CN-101664408-A Stabilization of hypoxia inducible factor (HIF) alpha FIBROGEN INC 2010-03-10 — — CN claimed
CN-101664551-A Stabilization of hypoxia inducible factor (HIF) alpha FIBROGEN INC 2010-03-10 — — CN claimed
EP-1412349-A2 PIPERAZINE OXYQUINOLINE (NAPHTHALINE) PLATELET ADENOSINE DIPHOSPHATE RECEPTOR ANTAGONISTS Schering Aktiengesellschaft (DE) 2004-04-28 — — EP claimed
WO-2002098856-A2 PIPERAZINE OXYQUINOLINE (NAPHTHALINE) PLATELET ADENOSINE DIPHOSPHATE RECEPTOR ANTAGONISTS SCHERING AKTIENGESELLSCHAFT (DE) 2002-12-12 — — WO claimed
CN-109232396-B Amide pyridine derivative and application thereof 聊城大学 2020-07-03 — — CN disclosed
CN-109232396-A Amide pyridine derivatives and application thereof 聊城大学 2019-01-18 — — CN disclosed
US-20110039879-A1 METHODS FOR INCREASING WHITE BLOOD CELLS FibroGen ,Inc. (US) 2011-02-17 — — US disclosed
US-20110039885-A1 METHODS FOR INCREASING ENDOTHELIAL PROGENITOR CELLS FIBROGEN, INC. (US) 2011-02-17 — — US disclosed
EP-2231157-A1 METHODS FOR INCREASING ENDOTHELIAL PROGENTIOR CELLS Fibrogen, Inc. (US) 2010-09-29 — — EP disclosed
EP-2231156-A1 METHODS FOR INCREASING WHITE BLOOD CELLS Fibrogen, Inc. (US) 2010-09-29 — — EP disclosed
US-5726305-A Substituted quinoline-2-carboxamides, their preparation and their use as pharmaceuticals, and intermediates HOECHST AKTIENGESELLSCHAFT (DE) 1998-03-10 — — US disclosed
US-5719164-A Substituted quinoline-2-carboxamides, their preparation and their use as pharmaceuticals, and intermediates HOECHST AKTIENGESELLSCHAFT (DE) 1998-02-17 — — US disclosed
CN-1154365-A Substituted quinoline-2-carboxamides, process for their preparation and their use as pharmaceuticals, and intermediates thereof HOECHST AG (DE) 1997-07-16 — — CN disclosed
EP-0765871-A1 Substituted Quinoline-2-carboxamides, their preparation and their use as prolyle-4-hydroxylase Inhibitors HOECHST AKTIENGESELLSCHAFT (DE) 1997-04-02 — — EP disclosed
US-5346907-A Cholecystokinin antagonists used in treatment or prevention of disorders of gastrointestinal, central nervous, appetite regulating or pain regulating systems ABBOTT LABORATORIES (US) 1994-09-13 — — US disclosed
WO-1991000725-A2 AMINO ACID ANALOG CCK ANTAGONISTS ABBOTT LABORATORIES (US) 1991-01-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110039879-A1 METHODS FOR INCREASING WHITE BLOOD CELLS THPO, MCL1, CD14 KDM4C 1725/4885ALDH1A1 284/4885GAA 1343/4885
US-20110039885-A1 METHODS FOR INCREASING ENDOTHELIAL PROGENITOR CELLS CXCL12, SDF4, LIPG KDM4C 1633/4885ALDH1A1 647/4885GAA 3166/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.